Auristatin

Auristatins are synthetic analogs of dolastatin 10 that function as highly potent microtubule-disrupting cytotoxins and are widely used as payloads in antibody-drug conjugates (ADCs) for targeted cancer therapy^[1][2]. Auristatin derivatives, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF), inhibit tubulin polymerization, disrupt microtubule dynamics, and induce mitotic arrest, thereby suppressing tumor cell proliferation^[1][3]. Mechanistically, structural studies demonstrate that auristatins destabilize microtubules through direct interaction with the tubulin network, providing the molecular basis for their antimitotic activity^[1]. In cancer models, the extreme potency of auristatins necessitates targeted delivery strategies, and ADC platforms exploit antibody-mediated internalization to release auristatin payloads selectively within tumor cells^[2][4]. Compared with related microtubule-targeting payload classes such as maytansinoids, auristatins remain among the most frequently deployed ADC warheads because of their high cytotoxic activity at low intracellular concentrations^[4]. Distinctions between major auristatin isoforms are also relevant for experimental design, as MMAE and MMAF differ in physicochemical properties and cellular behavior despite sharing a common microtubule-directed mechanism^[3]. For research applications, auristatin-based ADCs serve as established tools for investigating targeted cytotoxic delivery, microtubule biology, therapeutic resistance, and payload optimization in oncology models^[2][3][4].